Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/4073
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKyei-Barffour, I.-
dc.contributor.authorKwarkoh, R. K. B.-
dc.contributor.authorArthur, O. D.-
dc.contributor.authorAkwetey, S. A.-
dc.contributor.authorAcheampong, D. O.-
dc.contributor.authorAboagye, B.-
dc.contributor.authorBrah, A. S.-
dc.contributor.authorAmponsah, I. K.-
dc.contributor.authorAdokoh, C. K.-
dc.date.accessioned2023-11-15T11:33:36Z-
dc.date.available2023-11-15T11:33:36Z-
dc.date.issued2021-
dc.identifier.issn2405-8440-
dc.identifier.urihttp://hdl.handle.net/123456789/4073-
dc.description.abstractIntroduction: Increase in the prevalence of type-2 diabetes in Sub-Sahara Africa has created the need for robust treatment and management programs. However, an effective diabetes management program requires a high annual budget that most countries in this region cannot afford. That said, various plants and plant products in this region have either been confirmed and/or ethnopharmacologically used for the management of type-2 diabetes. Aim: To investigate the antidiabetic and insulin secretory effects of an alkaloidal extract derived from Zanthoxylum zanthoxyloides in normoglycemic and experimental diabetic rats. Materials and methods: Alkaloidal extract was prepared from leaves of Zanthoxylum zanthoxyloides (ZZAE). Nicotinamide/streptozotocin-induced type-2 diabetes was modeled in male Sprague Dawley rats weighing between 130 to 150 g. The experimental diabetic rats were grouped into six treatment groups [Model, 20% Tween20, chlorpropamide, and ZZAE (50, 100, and 150 mg/kg)], and one control group. Fasting blood glucose (FBG), and body weight were measured weekly. Rats were sacrificed 2 days after treatment under chloroform anesthesia to collect blood samples and to isolate major organs for biochemical, and histological analyses respectively. Islets of Langerhans were isolated from normoglycemic rats and co-cultured with ZZAE and chlorpropamide (10 μg/mL) to assess the insulin secretory effect of ZZAE. Results: ZZAE improved glucose kinetics curve in normoglycemic (p < 0.001) and experimental diabetic rats (p < 0.05) compared to the model. ZZAE (100 and 150 mg/kg) restored islets population, and improved kidney, and liver, histoarchitecture. ZZAE (150 mg/kg) improved post-treatment serum insulin levels compared to the model group (p < 0.001) and the Chlorpropamide group (p < 0.05). ZZAE also restored glycogen synthesis in skeletal muscles of experimental diabetic rats and stimulated insulin secretion in pancreatic islets of Langerhans isolated from normoglycemic rats. Conclusion: These results showed that ZZAE has active alkaloids that can be explored for diabetes management.en_US
dc.language.isoenen_US
dc.publisherElsevier.en_US
dc.relation.ispartofseriesVol.7;-
dc.relation.ispartofseriesHeliyon;-
dc.subjectGlucose Toleranceen_US
dc.subjectHistoarchitectureen_US
dc.subjectAntidiabeticen_US
dc.subjectAlkaloidal Extracten_US
dc.subjectGlycogen Synthesisen_US
dc.titleALKALOIDAL EXTRACT FROM ZANTHOXYLUM ZANTHOXYLOIDES STIMULATES INSULIN SECRETION IN NORMOGLYCEMIC AND NICOTINAMIDE/STREPTOZOTOCIN-INDUCED DIABETIC RATSen_US
dc.typeArticleen_US
Appears in Collections:School of Applied Economics and Management Sciences



Items in UDSspace are protected by copyright, with all rights reserved, unless otherwise indicated.